COMMUNIQUÉS West-GlobeNewswire

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

10/10/2024 - 13:00

Patients currently remain on study for continued treatment with TTX-MC138 No significant safety or dose limiting toxicities reported TTX-MC138, an antisense oligonucleotide conjugated to TransCode’s proprietary TTX [...]

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

10/10/2024 - 13:00

– Presentations will demonstrate high adherence and persistence, sustained attack reductions and patient preference for oral, once-daily ORLADEYO for hereditary angioedema – RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2024 ( [...]

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

10/10/2024 - 13:00

MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]

Tempest Extends Limited Duration Stockholder Rights Plan

10/10/2024 - 13:00

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated [...]

BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

10/10/2024 - 13:00

MELVILLE, N.Y., Oct. 10, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

10/10/2024 - 12:30

VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

10/10/2024 - 12:30

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic [...]

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

10/10/2024 - 11:01

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a [...]

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

10/10/2024 - 11:00

REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today [...]

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients

10/10/2024 - 10:42

Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy 1 Data showed that the daratumumab [...]

ICPO Foundation partners with the International Atomic Energy Agency (IAEA)

10/10/2024 - 10:15

The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for Precision Oncology (ICPO) [...]

MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity

10/10/2024 - 09:00

OXFORD, United Kingdom, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related [...]

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10/10/2024 - 08:28

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by EMA and Health Canada of the [...]

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science

10/10/2024 - 08:28

COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2024 ET LES EVENEMENTS CLEFS DE LA PERIODE Développement clinique Plateforme masitinib : Réexamen du dossier en cours par l’EMA et [...]

Pharming Group to report third quarter 2024 financial results on October 24

10/10/2024 - 08:00

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the [...]

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium

10/10/2024 - 08:00

10 October Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium LONDON, UK, 10 [...]

Aenitis Secures Strategic Funding to Redefine Bioproduction with Sole-In-Class Acoustofluidic Technology

10/10/2024 - 08:00

Aenitis Secures Strategic Funding to Redefine Bioproduction with Sole-In-Class Acoustofluidic Technology Aenitis is set to transform the bioproduction industry by addressing the increasing need for scalable, cost- [...]

Aenitis annonce un financement stratégique pour redéfinir les standards de la bioproduction grâce à sa technologie unique d’acoustofluidique

10/10/2024 - 08:00

Aenitis annonce un financement stratégique pour redéfinir les standards de la bioproduction grâce à sa technologie unique d’acoustofluidique Aenitis est en passe de transformer la bioproduction en répondant à la demande [...]

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

10/10/2024 - 07:15

Allschwil, Switzerland, October 10, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]